MediciNova, Inc.
MNOV
|
$1.34
-3.73%
9.3K
|
Health Technology
(0.0% 1d) (-2.9% 1m) (-38.2% 1y) (0.0% 2d) (0.0% 3d) (-6.3% 7d) (-4.89% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 65,721,970
http://www.medicinova.com
Sec Filling | Patents | 8 employees
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
acquisitions sclerosis cancer multiple sclerosis treatment
add to watch list Paper trade email alert is off
Press-releases
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
Published: 2024-04-02 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 2.01%
H: 4.61%
C: 0.0%
mn-166 presentation meeting trial results glioblastoma
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
Published: 2024-03-26 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 2.21%
H: 5.76%
C: 5.76%
mn-166 patent japan macular treatment
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
Published: 2024-03-20 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 2.7%
H: 2.67%
C: 0.2%
mn-001 presentation meeting
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
Published: 2024-03-12 (Crawled : 11:00) - biospace.com/
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 2.17%
H: 2.12%
C: -0.71%
mn-166 lung meeting results
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
Published: 2024-01-17 (Crawled : 11:00) - globenewswire.com
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 0.0%
H: 0.66%
C: -1.32%
mn-166 patent macular treatment grant china
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
Published: 2023-12-21 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 1.35%
H: 0.0%
C: -2.67%
mn-166 lung presentation meeting
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
Published: 2023-12-06 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 0.0%
H: 4.17%
C: 4.17%
mn-166 europe patent treatment grant
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
Published: 2023-11-19 (Crawled : 00:00) - globenewswire.com
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 11.8%
H: 8.54%
C: 3.52%
mn-166 meeting trial results glioblastoma
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
Published: 2023-10-27 (Crawled : 05:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -18.18%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -15.73%
H: 0.0%
C: 0.0%
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: -1.54%
treatment phenylketonuria therapy
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
Published: 2023-10-10 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 1.15%
H: 1.15%
C: -1.14%
mn-166 patent riluzole sclerosis treatment canada
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0001683168-24-000225 | 4 | 2024-01-11 | 2024-01-09 | Buy | A | 84000 | 84000 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Last 48 Hours Insiders Buying
MEGI | $11.975 1.87% 0.04% 140K
|
|
00:30
CTRN P 29000 | $22.25 0.14% 0.13% 100K
|
Retail Trade
|
22:00
CONN | $3.71 1.37% 1.35% 72K
|
Retail Trade
|
21:30
TGEN P 6000 | $0.6897 39.71% 2.3K
|
Utilities
|
18:30
CMTV P 700 | $15.74 17.43% 12K
|
Finance and Insurance
|
18:30
FNB | $13.63 2.17% 0.0% 2.5M
|
Finance
|
17:30
RMCF | $3.57 0.28% 2.8K
|
Consumer Non-Durables
|
20:10